Eye Exams for People With Diabetes

Annual eye exams for people with diabetes are one of the most important — and most commonly delayed — components of standard diabetes care. Diabetic retinopathy, the damage to the blood vessels of the retina caused by chronically elevated blood glucose, is the leading cause of new blindness in adults of working age in developed countries, and it is largely preventable through consistent blood glucose control and preventable from causing vision loss through timely detection and treatment. The reason annual screening is so critical is that diabetic retinopathy is completely asymptomatic in its early stages: the microscopic changes in retinal blood vessels that precede significant vision loss can be present for years without the person noticing any change in their sight. By the time visual symptoms appear — blurred vision, floaters, dark areas in the visual field, or sudden vision loss — the disease has often progressed to a stage that is harder to treat and less likely to result in full vision preservation. Annual dilated eye exams for people with diabetes detect retinopathy at stages when intervention is most effective, before the disease has a chance to cause irreversible damage.

What Happens During a Dilated Eye Exam for Diabetes

Understanding what to expect during eye exams for people with diabetes reduces the barrier of unfamiliarity and helps patients schedule and attend this critical annual screening:

• Dilation drops: The dilated eye exam begins with eye drops that dilate (widen) the pupils to allow the ophthalmologist or optometrist to see the full extent of the retina through the enlarged pupil opening. The drops take approximately 20–30 minutes to take full effect. During and after dilation, vision will be blurry — particularly close-up vision — and the eyes will be sensitive to light. This effect typically lasts 4–6 hours after the drops are administered, which means driving immediately after the exam may not be safe; bringing a driver or planning alternative transportation is advisable, particularly for the first dilated exam until you know how strongly your eyes respond to the dilation drops.
• Retinal examination: Once the pupils are dilated, the eye care specialist uses an ophthalmoscope (and often a slit lamp with various lenses) to examine the retina, optic nerve, macula, and retinal blood vessels in detail. The retinal blood vessels visible in the eye are among the few blood vessels in the body that can be directly visualized without surgery — and they provide a window into the microvascular damage that diabetes causes throughout the body. The examiner is specifically looking for microaneurysms (small bulges in retinal blood vessels that are the earliest sign of diabetic retinopathy), hemorrhages (bleeding into the retinal layers), exudates (deposits of lipid that leak from damaged vessels), cotton wool spots (areas of ischemia where blood flow has been interrupted), new vessel growth (neovascularization, the hallmark of proliferative retinopathy), and macular edema (swelling at the center of the retina that threatens central vision).
• Additional imaging when indicated: In addition to the ophthalmoscopic examination, many practices use retinal photography to document the appearance of the retina for comparison at future visits and for teleretinal screening programs. Optical coherence tomography (OCT) — a high-resolution imaging technique that produces cross-sectional images of the retinal layers — is increasingly used to detect and quantify diabetic macular edema, which can be present even when retinal appearance looks relatively normal. Fluorescein angiography (injection of a fluorescent dye to visualize retinal blood vessel function) is used when more detailed assessment of blood vessel leakage or ischemia is needed, typically when proliferative retinopathy or significant macular disease is suspected.
• What results you should receive: After the retinal examination, the eye care specialist should communicate the retinopathy status clearly: no retinopathy found, mild/moderate/severe non-proliferative diabetic retinopathy (NPDR), or proliferative diabetic retinopathy (PDR) — and whether diabetic macular edema (DME) is present. The retinopathy stage determines the recommended next-visit interval and whether treatment is needed. This information should also be communicated to your primary care diabetes provider so it can be incorporated into the overall diabetes management record.

How Often Do People With Diabetes Need Eye Exams

The frequency of eye exams for people with diabetes depends on both the presence and severity of existing retinopathy and on individual risk factors. The American Diabetes Association recommendations are:

• At Type 2 diabetes diagnosis: A dilated eye examination should be performed at the time of Type 2 diabetes diagnosis. Unlike Type 1 diabetes (where retinopathy rarely develops in the first 5 years after diagnosis), Type 2 diabetes often exists for years before formal diagnosis — meaning significant retinopathy may already be present at the time the diabetes is first identified. Many adults diagnosed with Type 2 diabetes already have some degree of retinopathy at diagnosis, making the initial eye exam at diagnosis both clinically and practically important.
• No retinopathy found — annually or biennially: Adults with Type 2 diabetes who have no evidence of retinopathy on dilated examination and have well-controlled blood glucose, blood pressure, and lipids may qualify for biennial (every 2 years) eye exams in some clinical guidelines, rather than strict annual exams. This decision should be made by the eye care specialist based on overall risk profile; annual exams remain the standard recommendation for most adults, and biennial intervals are only appropriate when the overall risk is judged to be low.
• Mild to moderate non-proliferative retinopathy — annually: Adults with mild or moderate NPDR on examination should continue annual dilated exams, with the understanding that the examiner will assess whether the disease has progressed and whether more frequent monitoring is warranted based on what is found at each visit.
• Severe non-proliferative or proliferative retinopathy — every 3–6 months: More severe retinopathy stages require much more frequent examination — typically every 3–6 months — so that the ophthalmologist can monitor for the development of high-risk features requiring laser photocoagulation or anti-VEGF treatment before vision-threatening complications occur. Proliferative diabetic retinopathy, in particular, can progress rapidly and requires prompt treatment when high-risk characteristics are identified.
• Diabetic macular edema — individualized, typically every 1–4 months during treatment: Diabetic macular edema — swelling at the macula that directly threatens central vision — is now treated with anti-VEGF injections (ranibizumab, aflibercept, bevacizumab) given every 1–2 months during the initial treatment phase, with monitoring visits between injections to assess treatment response. The treatment course and monitoring interval for diabetic macular edema is managed by a retinal specialist (vitreoretinal ophthalmologist) rather than a general ophthalmologist or optometrist. The complete diabetes monitoring framework that places eye exams in context alongside all other annual monitoring components is in our annual diabetes care checklist. The overall diabetes checkup schedule covering quarterly and annual visit content is in our diabetes checkups: what to expect guide. The blood glucose control that is the primary modifiable risk factor for diabetic retinopathy progression is monitored through the A1C test covered in our A1C testing schedule guide. The ADA’s diabetic eye health resources, the NIDDK’s diabetic eye disease information, and the National Eye Institute’s diabetic retinopathy resources provide authoritative clinical information on eye exams and diabetic eye disease for adults with diabetes.

Risk Factors That Accelerate Diabetic Retinopathy Progression

Understanding the modifiable risk factors for diabetic retinopathy progression helps adults with diabetes take concrete action beyond simply attending annual eye exams — the interval between exams is a period during which risk factor management directly determines how rapidly retinopathy develops and worsens:

• Blood glucose control (HbA1c) — the primary modifiable risk factor: The DCCT (Diabetes Control and Complications Trial) in Type 1 diabetes and the UKPDS in Type 2 diabetes both established that intensive blood glucose control (lower HbA1c) dramatically reduces the rate of development and progression of diabetic retinopathy. In the UKPDS, each 1 percentage point reduction in HbA1c was associated with approximately 35% reduction in the rate of microvascular complications including retinopathy. This dose-response relationship means that any improvement in blood glucose control — even if the target is not fully reached — reduces retinopathy risk proportionally. Conversely, chronically elevated blood glucose is the most powerful driver of retinopathy progression. The HbA1c measurement that tracks blood glucose control over time is covered in our A1C testing schedule guide.
• Blood pressure control: High blood pressure is an independent risk factor for diabetic retinopathy progression, separate from blood glucose — the UKPDS showed that blood pressure control reduces retinopathy progression risk nearly as much as blood glucose control does. Elevated blood pressure damages retinal blood vessels through mechanical shear stress and promotes the breakdown of the blood-retinal barrier. Adults with diabetes and hypertension face compounded retinal vascular risk and particularly benefit from reaching blood pressure below 130/80 mmHg. Blood pressure monitoring in diabetes is covered in our blood pressure monitoring in diabetes guide.
• Diabetes duration: The longer a person has had diabetes, the higher the cumulative probability of having developed some degree of retinopathy — regardless of how well blood glucose has been controlled during that period. This relationship emphasizes the importance of early blood glucose control from diagnosis, since the cumulative exposure to elevated glucose (even modest elevations that don’t trigger symptoms) drives retinopathy risk over decades. Adults who have had Type 2 diabetes for more than 15–20 years should not reduce vigilance about annual eye exams even if their glucose control has been good — duration itself is an independent risk factor.
• Dyslipidemia (elevated triglycerides, low HDL, elevated LDL): Abnormal lipid levels, particularly elevated serum triglycerides and elevated LDL cholesterol, are associated with increased risk of hard exudates in the retina and worsening diabetic macular edema. Statin therapy for LDL management and management of hypertriglyceridemia are therefore important components of retinopathy risk reduction in addition to their cardiovascular benefits. The lipid monitoring and management guide that covers cholesterol targets in diabetes is in our cholesterol monitoring in diabetes article.
• Pregnancy in women with diabetes: Pregnancy with pre-existing diabetes — either Type 1, Type 2, or diabetes identified before the pregnancy — is associated with accelerated retinopathy progression during the pregnancy. Women with diabetes who are planning pregnancy or who become pregnant should have dilated eye exams before conception (or early in the first trimester), and then at each trimester during the pregnancy, with additional follow-up in the postpartum period. Gestational diabetes (diabetes that develops during pregnancy in women without pre-existing diabetes) is generally not associated with diabetic retinopathy, as the duration of hyperglycemia is too short to produce significant retinal vascular damage.
• Nephropathy (kidney disease): Diabetic nephropathy (kidney disease from diabetes) and diabetic retinopathy share the same pathological mechanism — microvascular damage from chronically elevated blood glucose — and the two complications are strongly correlated. Adults with evidence of diabetic kidney disease (elevated urine albumin, reduced eGFR) have higher rates of diabetic retinopathy and should ensure that eye exam screening is current. Conversely, significant retinopathy in an adult not previously known to have kidney disease should prompt evaluation of kidney function. The kidney monitoring context is in our kidney tests for diabetes monitoring guide.

Treatment Options for Diabetic Retinopathy

When eye exams for people with diabetes detect retinopathy that has progressed to the point where treatment is needed, several effective interventions can prevent further vision loss and in some cases restore vision:

• Anti-VEGF injections (for diabetic macular edema and proliferative retinopathy): Anti-vascular endothelial growth factor (anti-VEGF) medications — ranibizumab (Lucentis), aflibercept (Eylea), and bevacizumab (Avastin, used off-label) — are injected directly into the vitreous cavity of the eye and block the abnormal blood vessel growth and vascular leakage that characterize proliferative retinopathy and diabetic macular edema. Multiple randomized clinical trials (DRCR Retina Network Protocol T and subsequent studies) have established anti-VEGF injections as the most effective treatment for center-involving diabetic macular edema that threatens central vision. Treatment typically requires monthly injections for an initial loading phase (3–6 injections), followed by a monitoring and maintenance phase where injection frequency is determined by the treatment response.
• Laser photocoagulation (for proliferative retinopathy): Laser treatment — historically the primary treatment for proliferative diabetic retinopathy — uses laser energy to create small burns in the peripheral retina, which reduces the retina’s oxygen demand and suppresses the VEGF signal that drives new abnormal blood vessel growth. Panretinal photocoagulation (PRP), which treats the peripheral retina with hundreds of laser spots, can prevent severe vision loss from proliferative retinopathy but typically results in some reduction of peripheral and night vision. In the current treatment landscape, anti-VEGF injections are often used as a primary or adjunct treatment for proliferative retinopathy, with laser reserved for cases that do not respond adequately or where the injection interval cannot be maintained.
• Vitrectomy (for advanced disease): When proliferative retinopathy has progressed to causing vitreous hemorrhage (bleeding into the gel of the eye) or tractional retinal detachment (where scar tissue pulls the retina away from its normal position), vitrectomy — surgical removal of the vitreous gel — is performed to clear the hemorrhage and release the traction on the retina. Vitrectomy is performed by vitreoretinal surgeons and carries meaningful visual recovery potential even in advanced disease, though outcomes depend heavily on whether the central retina (macula) has been detached. The complete context for all diabetes monitoring tests — including how retinopathy fits within the full monitoring system — is in our annual diabetes care checklist. The diabetes checkup guide that covers how eye exams fit within the broader monitoring schedule is in our diabetes checkups: what to expect article. The ADA’s diabetic eye health resources, the NIDDK’s diabetic eye disease information, and the National Eye Institute’s diabetic retinopathy resources provide authoritative information on treatment options and outcomes for diabetic eye disease.

Other Eye Conditions More Common in People With Diabetes

While diabetic retinopathy is the primary focus of annual eye exams for people with diabetes, adults with diabetes are also at increased risk of several other ocular conditions that the dilated examination can detect:

• Cataracts: Cataracts (clouding of the crystalline lens) develop earlier and progress faster in adults with diabetes compared to adults without diabetes. The elevated blood glucose associated with diabetes promotes glycosylation of lens proteins, accelerating lens opacity. Adults with poorly controlled diabetes may develop cataracts a decade or more earlier than age-matched adults without diabetes. Cataracts cause progressive blurring and glare sensitivity that are often mistaken for diabetic macular edema or retinopathy-related vision loss; the dilated exam distinguishes between them. Cataract surgery is highly effective in adults with diabetes, but post-surgical retinopathy management may be more complex — the ophthalmologist will assess whether retinopathy treatment is needed before or after surgery to optimize visual outcomes.
• Glaucoma: Open-angle glaucoma is approximately twice as common in adults with diabetes compared to the general population. Glaucoma involves elevated intraocular pressure that damages the optic nerve, causing progressive peripheral vision loss that is often not noticed until significant damage has occurred. Annual eye exams for people with diabetes typically include intraocular pressure measurement and optic nerve assessment — the key tests for glaucoma screening. Neovascular glaucoma, a particularly aggressive form, can develop as a direct complication of proliferative diabetic retinopathy when new abnormal blood vessels grow into the drainage angle of the eye, blocking fluid outflow and causing sudden, severe intraocular pressure elevation.
• Diabetic papillopathy: A relatively rare condition, diabetic papillopathy involves optic disc swelling (papilledema-like changes) in adults with diabetes, usually with relatively preserved vision. It is typically self-limiting and resolves over weeks to months, but requires monitoring to distinguish from other causes of optic disc swelling and to confirm resolution.
• Retinal vein occlusion: Branch and central retinal vein occlusions — blockages of the veins that drain blood from the retina — are more common in adults with diabetes and hypertension. They can cause sudden painless vision loss in the affected area and may require anti-VEGF treatment for the associated macular edema. Detecting vein occlusions during annual exams and referring for appropriate management prevents further vision deterioration. The comprehensive monitoring schedule that ensures all diabetes complications are tracked consistently is in our annual diabetes care checklist. The kidney disease that often co-exists with advanced retinopathy is monitored through the tests covered in our kidney tests for diabetes monitoring guide and our eGFR and kidney function in diabetes article. The blood glucose management that is the primary tool for retinopathy prevention is supported by the medication guidance in our diabetes medications overview and the dietary approach in our diabetes meal planning guide.

The most important action any adult with diabetes can take regarding diabetic eye disease is to attend annual dilated eye exams consistently, even when — especially when — vision feels normal and there are no symptoms. The asymptotic nature of early and moderate diabetic retinopathy means that the absence of symptoms provides no reliable information about the current state of the retina. The interval between a normal retinal exam and the first stage of vision-threatening retinopathy can be short in patients with poorly controlled risk factors; annual examination provides the opportunity to detect that transition and intervene before irreversible damage occurs. Adults who have not had a dilated eye exam in the past year and who have Type 2 diabetes should schedule one — not because they have symptoms, but because they do not have symptoms and symptoms are not a reliable guide to retinal health in diabetes. The National Eye Institute and the American Diabetes Association both maintain updated resources on diabetic eye disease that complement the clinical monitoring provided by annual eye exams.

Sources: American Diabetes Association — Standards of Medical Care in Diabetes, diabetic retinopathy screening recommendations; NIDDK — diabetic eye disease resources; National Eye Institute — diabetic retinopathy information; ADA diabetic retinopathy staging classification (mild, moderate, severe NPDR; PDR); diabetic macular edema diagnosis and anti-VEGF treatment protocols; dilated eye exam procedure and dilation drop effects; retinal photography and OCT use in diabetic retinopathy screening; DRCR Retina Network clinical trial data on anti-VEGF for diabetic macular edema; diabetic retinopathy prevalence data from National Health Interview Survey and NHANES; Early Treatment Diabetic Retinopathy Study (ETDRS) risk factor data; American Academy of Ophthalmology preferred practice patterns for diabetic retinopathy.